Immediate Impact

2 from Science/Nature 50 standout
Sub-graph 1 of 25

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
2 intermediate papers

Works of T. Kumke being referenced

OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
2019
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
2018

Author Peers

Author Last Decade Papers Cites
T. Kumke 82 53 115 86 49 369
Zhenrui Cao 6 22 19 74 26 377
Zhihua Tu 41 35 24 54 25 327
Shyam K. Nair 10 23 22 83 27 314
Yuan Gao 11 8 47 41 30 410
Jiaxin Zhou 82 3 111 29 21 350
Qiaoling Guo 14 28 30 47 21 322
Yanbin He 4 9 66 77 28 363
Jiacun Chen 4 17 30 64 33 374
Annette Bolton 3 4 149 105 20 340
Arindam Chakraborty 2 6 84 76 39 327

All Works

Loading papers...

Rankless by CCL
2026